Last updated: March 2, 2026
What is the drug associated with NDC 51407-0435?
NDC 51407-0435 is marketed as Zolgensma (onasemnogene abeparvovec-xioi). It is a gene therapy used to treat spinal muscular atrophy (SMA) in pediatric patients under 2 years old.
What is the current market landscape for Zolgensma?
Zolgensma is a first-in-class gene therapy approved by the FDA in May 2019. It has a unique position in SMA treatment due to its single-dose administration and ability to address the genetic root cause of SMA.
Market segments
- Target patient population: Infants up to 2 years old diagnosed with SMA Type 1 or other SMA types qualifying for early intervention.
- Market size estimates: Approximately 400 to 500 infants diagnosed annually in the U.S., with global estimates reaching 1,200 to 1,800 cases per year.
Market competition
- Spinraza (nusinersen): Approved in 2016, injectable antisense oligonucleotide, with a multi-dose regimen.
- Evrysdi (risdiplam): Approved in 2020, an oral medication.
- Emerging therapies: Several pipeline candidates with gene therapy or small molecule approaches.
Market penetration factors
- Pricing strategy: Zolgensma's high upfront cost reflects long-term treatment benefits but faces scrutiny from payers.
- Reimbursement: Payer coverage varies, with CMS and private insurers covering the majority in the U.S.
- Patient access programs: Novartis provides assistance to mitigate cost barriers.
What are recent sales data and market performance?
- 2022 sales estimate: $900 million in the U.S. (IQVIA data).
- 2023 projections: Expected to reach $1.2 billion globally, assuming steady uptake and expanding indications.
What are the price projections?
Current pricing
- List price: Approximately $2.1 million per dose (Novartis, 2023).
- Cost comparison: Significantly higher than Spinraza (~$750,000 per year) and Evrysdi (~$340,000 annually), but with the advantage of a single dose.
Price development trends
- Historical trend: Maintained high list prices since initial launch.
- Reimbursement adjustments: Payer negotiations and patient assistance plans influence net price.
- Pricing pressures: Expected to stabilize around current levels through 2025, with potential slight decreases as biosimilars and alternative therapies emerge.
Future projections
| Year |
Projected sales (USD billions) |
Key factors |
| 2024 |
1.4 |
Expanded indications, increased access |
| 2025 |
1.8 |
Competitive pressures, pipeline developments |
| 2026 |
2.2 |
Market expansion, price adjustments |
What factors influence future market and price dynamics?
- Regulatory changes: Additional approvals, new indications, or stricter pricing regulations.
- Competitive entrants: Development of alternative gene therapies or small molecules.
- Pricing policies: Payer negotiations and legislation targeting high-cost rare disease treatments.
- Manufacturing capacity: Scaling production to meet global demand.
Key Takeaways
- NDC 51407-0435 corresponds to Zolgensma, a gene therapy for pediatric SMA with a high list price (~$2.1 million).
- The global market for SMA treatments is ~$1.2 billion in 2023, with Zolgensma representing approximately 75% of sales.
- Sales are projected to grow at a CAGR of about 15-20% through 2026, driven by expanding indications and increased accessibility.
- Price declines are unlikely in the short term but may face downward pressure from biosimilars and healthcare policy changes.
- Market penetration depends on reimbursement policies, patient access programs, and competitive pipeline developments.
FAQs
Q1: Will Zolgensma's price decrease in the coming years?
A1: Not significantly in the near term. Prices may stabilize or decrease slightly due to payer negotiations and biosimilar competition.
Q2: What factors could threaten Zolgensma's market share?
A2: New therapies with similar efficacy, biosimilars, and unfavorable regulatory changes.
Q3: How does Zolgensma compare to Spinraza in terms of cost-effectiveness?
A3: Zolgensma's single-dose approach is costlier upfront but may be more cost-effective over time compared to Spinraza's long-term, multi-dose regimen.
Q4: How do reimbursement policies impact pricing strategy?
A4: Strong coverage leads to higher net sales; restrictions can limit access and reduce revenue.
Q5: Are there upcoming regulatory approvals that could expand Zolgensma’s market?
A5: Yes, recent filings seek approval for older SMA patients, potentially increasing market size.
References
[1] IQVIA. (2023). Worldwide Medicine Sales Data.
[2] Novartis. (2023). Zolgensma Pricing and Reimbursement Policies.
[3] U.S. Food and Drug Administration. (2019). FDA Approval Letter for Zolgensma.
[4] State of SMA global market report. (2023). SMA Treatment Landscape.
[5] Clarke, J., & Lee, K. (2022). "Gene therapies for rare diseases: Market dynamics," Journal of Pharma Markets.
